Teva Pharmaceutical Industries (TEVA) Revenue (2016 - 2026)

Teva Pharmaceutical Industries has disclosed Revenue across 11 years of filings, most recently posting $4.0 billion for Q1 2026.

• Quarterly Revenue rose 2.34% year-over-year to $4.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.3 billion (up 13.49% YoY) and the FY2025 annual result came in at $17.3 billion, up 4.32% from the prior year.
• Revenue declined to $4.0 billion in Q1 2026, from $4.7 billion in the prior quarter.
• Over five years, Revenue peaked at $4.7 billion in Q4 2025 and troughed at $2.9 billion in Q4 2024.
• A 5-year average of $4.0 billion and a median of $3.9 billion in 2022 frame the typical range for Revenue.
• Annual changes were most pronounced in 2024 — Revenue plunged 34.93% — and 2025, when it jumped 62.45%.
• Tracing TEVA's Revenue over 5 years: stood at $3.9 billion in 2022, then advanced by 14.75% to $4.5 billion in 2023, then tumbled by 34.93% to $2.9 billion in 2024, then jumped by 62.45% to $4.7 billion in 2025, then dropped by 15.47% to $4.0 billion in 2026.
• Business Quant data shows TEVA's Revenue at $4.0 billion in Q1 2026, $4.7 billion in Q4 2025, and $4.5 billion in Q3 2025.